Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Central Neuropathic Pain Clear all
Completed Phase 3 Interventional Results available

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

NCT00232141
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Clinical Trial of Wireless CranioFacial Nerve Stimulation (CFNS) for the Treatment of CranioFacial Neuropathic Pain

NCT02729480
View directory record Official record
Conditions
Facial Pain
Interventions
Halo Craniofacial Nerve Stimulator System
Device
Lead sponsor
Curonix LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Canton, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Jul 22, 2026, 2:25 PM EDT
Active, not recruiting Not applicable Interventional

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

NCT04917796
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Nerve Pain, Neuropathy, Neuropathy, Painful, Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Electroacupuncture, Sham Acupuncture
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI

NCT05630235
View directory record Official record
Conditions
SCI - Spinal Cord Injury, Neuropathic Pain
Interventions
CBD/CBD-A, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Nitrous Oxide as Treatment for Fibromyalgia

NCT05357066
View directory record Official record
Conditions
Fibromyalgia, Central Neuropathic Pain
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Terminated Not applicable Interventional

Modulating Neuropathic Pain With Transcranial Direct Current Stimulation

NCT04581525
View directory record Official record
Conditions
Pain, Neuropathic, Complex Regional Pain Syndromes, Phantom Limb Pain, Spinal Cord Injuries
Interventions
transcranial direct current stimulation
Device
Lead sponsor
Susan McDowell
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 22, 2026, 2:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MR Spectroscopy as a Diagnostic and Outcome Measure in Pain and SCI

NCT00561782
View directory record Official record
Conditions
Spinal Cord Injury, Hyperalgesia, Secondary, Hyperalgesic Sensations
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 1 Interventional

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

NCT06810245
View directory record Official record
Conditions
Chronic Osteoarthritis Pain, Chronic Low Back Pain
Interventions
PIPE-791, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Marietta, Georgia • Hartsdale, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 3 Interventional Results available

Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

NCT05639946
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
brivaracetam, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-639, pregabalin, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

NCT00733096
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
etanercept, methylprednisolone, normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 7, 2012 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Immersive Virtual Reality for Chronic Neuropathic Pain After Spinal Cord Injury: A Feasibility Trial

NCT04700033
View directory record Official record
Conditions
Neuralgia, Spinal Cord Injuries, Chronic Pain
Interventions
Somatic IVR (sIVR), Distractive IVR (dIVR), Control IVR (cIVR)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Jul 22, 2026, 2:25 PM EDT
Terminated Phase 3 Interventional Results available

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217
View directory record Official record
Conditions
Neuropathy
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • North Hollywood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional Results available

Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy

NCT01592344
View directory record Official record
Conditions
Chronic Pain
Interventions
StimRouter - active stimulation, StimRouter - Control
Device
Lead sponsor
Bioness Inc
Industry
Eligibility
22 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
13
States / cities
Scottsdale, Arizona • Napa, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Jul 22, 2026, 2:25 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2010 · Synced Jul 22, 2026, 2:25 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

PET/MRI in the Diagnosis of Chronic Pain

NCT03556137
View directory record Official record
Conditions
Neuropathic Pain, Nociceptive Pain, Mixed Pain (Nociceptive and Neuropathic), Spinal Pain, Radiculopathy, Myelopathy, Neurogenic Claudication
Interventions
[18F]FTC-146
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Jul 22, 2026, 2:25 PM EDT
Terminated Phase 4 Interventional Results available

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

NCT00414453
View directory record Official record
Conditions
Neuropathic Pain, Chronic Pain, Multiple Sclerosis
Interventions
Lidocaine patch 5%, Extended-release oxycodone, Placebo extended-release oxycodone pills, Placebo lidocaine patches
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

NCT01324232
View directory record Official record
Conditions
Central Neuropathic Pain, Multiple Sclerosis
Interventions
AVP-923-45, AVP-923-30, AVP-923-20, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jul 22, 2026, 2:25 PM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

NCT04144972
View directory record Official record
Conditions
Spinal Cord Injuries, Nerve Injury, Pain, Postoperative, Post Herpetic Neuralgia, Complex Regional Pain Syndromes, Post-Stroke Pain, Post Radiation Brain Injury, Post Radiation Plexopathy, Nerve Root Avulsion
Interventions
Medtronic Summit RC+S or Percept RC
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2 Interventional

Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury

NCT00488969
View directory record Official record
Conditions
Neuropathic Pain, Spinal Cord Injury
Interventions
Modified-release morphine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Vaporized Cannabis and Spinal Cord Injury Pain

NCT01555983
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Diseases
Interventions
Vaporization of Cannabis
Drug
Lead sponsor
Barth Wilsey
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI

NCT04256603
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Gabapentin, No gabapentin
Drug · Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Not applicable Interventional

Virtual Reality Walking for Neuropathic Pain in Spinal Cord Injury

NCT03735017
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Non-Interactive Virtual Reality Walking, Interactive Virtual Reality Walking
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 2:25 PM EDT
Completed Phase 3 Interventional

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT00228605
View directory record Official record
Conditions
Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
38
States / cities
Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 22, 2026, 2:25 PM EDT